 | |
- close
- close
|
Stock Blog Hub
9 hrs ago
Comment
This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a...
Business Wire
Nov 20
Comment
POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in
The Economist
Nov 10
Comment
The future's so frightening it might not be that bad
FELIX SALMON comments on a book on financial reform by Bob Pozen and concludes:What’s pretty obvious though is that most of Pozen’s recommendations will...
Stock Blog Hub
Oct 28
Comment
Vimovo Demonstrates Benefit Over Naproxen
Yesterday, at the American College of Gastroenterology meeting in San Diego, Pozen (POZN) released data from two phase III trials comparing Vimovo (formerly PN400) to enteric-coasted naproxen (ECN) in...
StreetInsider.com
Oct 28
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/POZEN+%28POZN%29+Beats+Estimates+by+5c%2C+Reports+Q3+EPS+of+%240.22/5050614.html for the full story.
Business Wire
Oct 27
Comment
POZEN Inc. (NASDAQ: POZN) announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly
Stock Blog Hub
Oct 20
Comment
Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We
see the fundamentals as strong and the valuation as low.
We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen...
StreetInsider.com
Oct 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AstraZeneca+%28AZN%29+and+POZEN+%28POZN%29+Announced+Pivotal+Data+from+VIMOVO+Studies+at+ACR+2009+Meeting/5025582.html for the full story.
PR Newswire
Oct 19
Comment
PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
POZN AT A GLANCE
References
| ||||||
|
|
